Group items matching

in title, tags, annotations or url

The NHS has secured a deal for 'Pembrolizumab' to treat women with triple-negative breast cancer. Up to 1,600 women a year affected by high risk triple-negative breast cancer are set to benefit from the confidential deal struck by the NHS and the Merck Sharp and Dohme's (MSD), manufacturer of Pembrolizumab. Triple-negative breast cancer affects around 8,000 women a year - accounting for 15% of all breast cancer cases. This will be the 25th breast cancer treatment fast-tracked to patients through funding from the Cancer Drugs Fund and the second treatment for triple negative breast cancer to be introduced this year on the NHS. NHS chief executive, Amanda Pritchard, said: "This is a hugely significant moment for women - the NHS has struck a new deal to roll out a potentially life-saving drug for patients suffering with the most aggressive form of breast cancer that has been traditionally very difficult to treat.

The National Institute for Health and Care Excellence (NICE) has recommended pembrolizumab in combination with chemotherapy (paclitaxel or nab-paclitaxel) which is said to benefit people with triple negative breast cancer. Clinical trial evidence shows that, compared with paclitaxel, pembrolizumab combination increases how long people have before their cancer gets worse and how long they live. NICE already recommends atezolizumab in combination with chemotherapy for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer. Atezolizumab combination is recommended by NICE for people with IC equal to or greater than 1%. "This means that some people who can't have atezolizumab combination could be eligible for pembrolizumab combination," said NICE. NICE's independent appraisal committee also agreed that the pembrolizumab combination meets the higher cost-effectiveness threshold for life-extending treatments for people with a short life expectancy. Given by injection every 3 weeks, pembrolizumab (also called Keytruda and made by Merck Sharp and Dohme) is a type of immunotherapy that specifically targets triple negative breast cancer. It works by blocking the activity of a protein known as PD-L1 which is produced in larger amounts on cancerous cells than normal cells. By blocking PD-L1 it helps the person's own immune cells to attack the cancer.

Chronic pain is a type of pain that usually lasts for weeks to months. This pain can come and go, and it can be anywhere in the body. Chronic pain can lead to anxiety, depression, and insomnia. Chronic pain is quite different from acute pain and there are some differences between the two types. People usually experience severe pain, when it is injured by a broken bone or a cut on the skin. This pain does not last long. Pain is not something that can be ignored. If it grows, it should be fixed. As fear and pain persist, one begins to think negatively. Long-term negative thoughts begin to form in his mind, a process called fear conditioning. This factor causes an increase in blood pressure and anxiety disorders. Chronic pain is difficult to treat, and results in increased pain, fear, and negative thoughts. Extreme levels of fear lead to more pain, and the cycle of pain threats can be difficult to break. One of the best pills used to treat body pain symptoms is Hydrocodone 325mg, which you can easily buy from any trusted online pharmacy, such as Pharma Health Online.

The National Pharmacy Association (NPA) survey revealed that 93 per cent of respondents experienced 'at least one month' of negative cash flow across their pharmacy business in 2022. Nine out of 10 pharmacy owners responding to NPA survey said they made a net loss dispensing medicines for the NHS during 2022, for at least one month of the year. According to the poll, 48 per cent of them lost money on this core NHS service for six months or more. 45 per cent said their overall outgoings had exceeded overall income in at least six months of the year. NPA Chair Andrew Lane said: "This survey shows the bleak financial reality facing many independent pharmacies after years of underfunding. Dispensing at a loss and negative cashflow is clearly unsustainable." "This funding crisis must be addressed urgently or pharmacies will fall into a spiral of declining services and ultimately widespread closures, he added. "Tragically, the story is playing out very much in line with independent research commissioned by the NPA last year, which warned of a nationwide financial emergency in our sector."

The minimum Covid-19 self-isolation period in England will be cut to five days from seven if someone tests negative twice, health secretary Sajid Javid said on Thursday (January 13) - a move that could reduce staffing disruption in businesses and infrastructure. The rapid spread of the Omicron variant has fuelled a spike in Covid-19 cases to record highs in Britain, and the surge has cause major disruption to the staffing of hospitals, schools and transport as staff have to self-isolate. "We've made the decision to reduce the minimum self-isolation period to five full days in England," Javid told parliament. "From Monday, people can test twice before they go, leaving isolation at the start of day six." The government had previously reduced isolation period to seven days from 10 days to people in England who get a negative result on a rapid lateral flow test two days in a row.

The UK's Health Security Agency (UKHSA) said mistakes at a testing laboratory led to misreporting of tens of thousands of positive COVID-19 cases as negative and may have resulted in the deaths of about 20 people. Britain has one of the highest coronavirus death tolls in the world, with more than 177,000 deaths since the pandemic started in 2020. Many experts have said the contact tracing programme fell well short of the "world-beating" system the government had promised. An investigation by the government agency responsible for responding to public health emergencies said the Immensa laboratory in central England was found to have misreported around 39,000 tests as negative when they should have been positive between September 2 and October 12 last year.

Community Pharmacy England (CPE) to host a Parliamentary drop-in event in July to brief MPs and Peers about the ongoing medicines supply chain issues that are negatively affecting pharmacies and their patients across the country. CPE's Pressures Survey earlier this year highlighted the extent of both the operational and financial impacts of medicines supply issues on pharmacy businesses, therefore it has continued to hear from both pharmacy owners and others about the problems. The event aims to ensure that MPs understand the problems and their impact on pharmacies. Peter Dowd MP is hosting the event, joined by representatives from Community Pharmacy England, the Nuffield Trust, patient groups and more. The event will also be another opportunity to talk to MPs from across the political spectrum about the very serious situation that community pharmacies still find themselves in and the need for further investment in the sector. Janet Morrison OBE, Chief executive of Community Pharmacy England said: "The results of our Pressures Survey earlier this year showed just how much supply issues are continuing to negatively impact pharmacy businesses and all those who work in them. The survey found that almost all pharmacy owners (97%) are facing significant increases in wholesaler and medicine supply issues, with 71% saying this was leading to delays in prescriptions being issued.

Pharmaceutical recalls are complicated and expensive, just like in any other business. Pharmaceutical recalls, however, pose a further risk because they might change both short- and long-term health effects. To ensure smooth recalls with few negative effects on public health, it is crucial to understand the pharmaceutical product recall procedure and the roles of each key player. Throughout the recall procedure, patient safety is crucially ensured by the FDA, pharmaceutical companies, pharmacy technicians, and other healthcare professionals. Learning about pharma recalls, procedures, and responsibilities is essential for guaranteeing patient safety for key actors like the Food and Drug Administration (FDA), manufacturers, and other medical specialists. RECALL CLASSIFICATIONS Recalls can fall into one of three categories-class I, II, or III-with class I being the most serious and lethal. Products that have the potential to result in serious, permanent complications or death are subject to Class I recalls. Class II recalls are recommended for product flaws that have a low likelihood of harmful events or that can result in reversible side effects. Last but not least, class III recalls typically arise from problems with packaging that do not pose a risk. Since they are frequently issued out of an abundance of prudence rather than due to any negative impacts, many people may even describe this kind of recall as benign.

A lot of women suffer silently because of weight problems. Weight issues do not only have a bearing on one's body but also has a negative impact on the mind. A lot of ladies hate the summers and feel terrible about the fact that when the rest of...

A lot of women suffer silently because of weight problems. Weight issues do not only have a bearing on one's body but also has a negative impact on the mind. A lot of ladies hate the summers and feel terrible about the fact that when the rest of...

You think thousands of thoughts each day. You talk to yourself more than anyone else. You are your most trusted advisor and confidant. Many of the conversations that you have with yourself you would never share with anyone else because to do so would expose the "real" you. The you that is filled with self doubt, worries, sadness, guilt, hurts and disappointments.

Consumption of salt, it states both the positive and negative sides of salt and adds some research reports to add more impact to the writing

Consumption of salt, it states both the positive and negative sides of salt and adds some research reports to add more impact to the writing

More than 500,000 women in England have benefitted from cheaper hormone replacement therapy (HRT) since the launch of the HRT prescription prepayment certificates (PPC) on 1 April last year, according to the Department of Health and Social Care (DHSC). HRT is the main treatment for negative menopause symptoms that can impact all areas of a woman's life. Introduced as part of the government's Women's Health Strategy, which made menopause a priority area, the HRT PPC reduced prescription costs to just £19.30 per year, helping patients save hundreds of pounds in prescription charges. The DHSC has confirmed that more than £11 million was saved by women using the PPC in the last nine months. Using the HRT PPC, patients can get a range of HRT items, including patches, tablets, and topical preparations at reduced prices, and they can use it many times as needed throughout the year.

...Do not take steroids. Steroids have been proven to interrupt the body's ability to produce natural hormones. Steroids can also have a negative effect on your liver, as well as lowering "good" cholesterol, and often causes men to develop some breast tissue... Enhance Your Body With These Bodybuilding Tips

There are many Benefits of meditation and it can be easily practiced on regular basis. Meditation has no negative side effects. Click for now for more details.

Rheumatoid arthritis is a disease that weakens the bones of the body and cause many other problems due to severe pain. It also has negative impacts on blood vessels, lungs, heart, muscles, and tissues. RA causes multi disorders in the body.

Rheumatoid arthritis is a disease that weakens the bones of the body and cause many other problems due to severe pain. It also has negative impacts on blood vessels, lungs, heart, muscles, and tissues. RA causes multi disorders in the body.

Persons having prostate cancer or breast cancer cannot use testosterone replacement therapy because it can cause the cancer to grow more rapidly. Testosterone therapy is used to improve low T levels in human body. However, it has number of negative impacts that everyone should know before using it.

Refurbished B. Braun Horizon NXT Infusion IV Pump The Refurbished B. Braun Horizon NXT Infusion IV Pump is intended for use with B. Braun Horizon I.V. sets to regulate the flow of primary and secondary fluids when positive pressure is required. The infusion system features the capability of delivering fluid from a negative head height, and provides volumetric accuracy for all standard I.V. fluids, including blood, lipids and TPN.